Sequencing Immunotherapy in Advanced-Stage Lung Cancer
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br />
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.
There had been a lot of debate about the timing of when patients should receive a PD-1 inhibitor, Garon explains.
Results of the KEYNOTE-024 study ended that debate when they showed patients with high levels of staining for PD-L1 were more likely to have an improvement in progression-free survival (PFS) if they received pembrolizumab (Keytruda) over chemotherapy. Additionally, there was a survival advantage seen in patients who received the PD-1 inhibitor as their initial therapy.
There is now a debate once again with the approval of carboplatin, pemetrexed, and pembrolizumab, based on results of the KEYNOTE-021 study.
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
February 17th 2025During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.
Read More
